EirGenix provides comprehensive cell line development services from DNA replication to the generation of stable producer cell lines for downstream process development and manufacturing, with systematic evaluation of expression systems and optimization to meet or exceed project requirements.

EirGenix provides end-to-end CDMO services for the development, analytical testing, and GMP manufacturing of biopharmaceuticals from pre-clinical to commercial scale. Leveraging strong process development capabilities in microbial and mammalian systems, we deliver optimized solutions across recombinant proteins, plasmid DNA, fusion proteins, monoclonal antibodies, and biosimilars.

We provide high-quality, cost-effective analytical services to support biopharmaceutical development and GMP manufacturing from pre-clinical to commercial scale. Our capabilities include analytical method development and validation during R&D, with coordinated transfer to the quality control team for GMP production, ensuring reliable and regulatory-compliant testing throughout the product lifecycle.

EirGenix provides high-quality, cost-effective contract development and manufacturing services, supporting clients in development, analytical testing, and GMP manufacturing of biopharmaceuticals from pre-clinical to commercial scale. We have a proven track record of inspections by regulatory authorities, including  EMA, TFDA, and others, and support commercial-scale production of successfully marketed products.

EirGenix provides high-quality, cost-effective contract development and manufacturing services, supporting biopharmaceutical development, analytical testing, and manufacturing from pre-clinical through commercial stages.

EirGenix offers comprehensive, integrated services for the development and manufacturing of antibody-drug conjugates (ADCs) as well as a broad range of other conjugates, including non-cytotoxic conjugates. By leveraging the capabilities of our strategic partner, Formosa Laboratories, Inc.—a leading manufacturer of highly potent active pharmaceutical ingredients—we ensure efficient, high-quality project execution across all stages of conjugate development. Our flexible platform and deep expertise allow us to support both cytotoxic and non-cytotoxic conjugates, enabling drug development projects to move seamlessly from concept to clinical-ready products.